What stage does H.I.G. HealthBridge Partners invest at?

H.I.G. HealthBridge Partners invests at the Growth stage.

What is H.I.G. HealthBridge Partners's typical check size?

H.I.G. HealthBridge Partners typically writes checks of $5M – $40M.

What sectors does H.I.G. HealthBridge Partners focus on?

H.I.G. HealthBridge Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is H.I.G. HealthBridge Partners located?

H.I.G. HealthBridge Partners is headquartered in Miami, US.

H.I.G. HealthBridge Partners

Growth equity

Miami · Growth · 9 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

H.I.G. HealthBridge Capital Partners is a growth equity fund focused on growth-stage healthcare companies, aiming to improve patient outcomes while lowering the total cost of healthcare. Its investment team brings experience across pharma, biotech, medical devices, diagnostics, and related services. Operating as part of the broader H.I.G. platform with extensive resources, the firm partners with founders and management teams to drive operational improvements and build market-leading positions. It emphasizes value creation, working alongside portfolio company leadership to establish stronger, more successful businesses across a range of healthcare-related sectors.

Invests inBiotech Digital Health Healthtech Medical DevicesAsia-PacificEuropeGlobalLatin AmericaMiamiMiddle East & North AfricaNorth AmericaUnited States

Source: firm website, verified Aug 3, 2026.

Stage

Growth

Check

$5M – $40M

Miami, Florida, US

Instruments

Equity

Founded

1993

AUM

$75B

Tracked investments

Team · 9 people

from the firm's website & public directories

Sami Mnaymneh· Founder and Executive Chairman

Sami Mnaymneh is a Founder and Executive Chairman of H.I.G., which he co-founded in 1993 and led as CEO until 2026, and he approves the firm's capital commitments. Before H.I.G., he was a Managing Director at The Blackstone Group and began his career at Morgan Stanley in New York. He holds a B.A. from Columbia University and a J.D. and M.B.A. from Harvard Law School and Harvard Business School.

Tony Tamer· Founder and Executive Chairman· Miami, Florida, United Statesin

Tony Tamer is a Founder and Executive Chairman of H.I.G. Capital, which he helped establish in 1993, and he approves the firm's capital commitments. Before H.I.G., he was a partner at Bain & Company and has worked with early-stage and middle-market companies. He earned a B.S. from Rutgers University, an M.B.A. from Harvard Business School, and an M.S. in Electrical Engineering from Stanford University.

Alex Zisson· Managing Director

a•••@higcapital.comreveal

Gwen Watanabe· Managing Director

g•••@higcapital.comreveal

Dylan Harmon· Principal

d•••@higcapital.comreveal

Brian Schwartz· CEO

Brian Schwartz is the Chief Executive Officer of H.I.G. Capital, where he sets the firm's strategic direction and serves on its Executive Committee. He joined H.I.G. in 1994 and has held senior leadership roles across the firm's Private Equity, Credit, and Real Assets platforms, including six years as Co-President. Earlier in his career he worked in strategic planning at PepsiCo and investment banking at Dillon, Read & Co., and he holds a B.S. from the University of Pennsylvania and an M.B.A. from Harvard Business School.

Douglas Berman· Co-President

Douglas Berman is Co-President of H.I.G. Capital, which he joined in 1996 and where he has been an Executive Managing Director since 2007. Earlier in his tenure he led the acquisition of more than 40 businesses for the firm. Before H.I.G., he worked as a consultant at Bain & Company. He holds a B.A. in Economics from the University of Virginia and an M.B.A. from The Wharton School of the University of Pennsylvania.

Rick Rosen· Co-President· Miami, Florida, United Statesin

Rick Rosen is Co-President of H.I.G. Capital, where he helps direct the firm's day-to-day operations and serves on the investment committees for all H.I.G. funds. He has more than 25 years of private equity and M&A experience and joined H.I.G. in 1998, having held leadership roles across several of the firm's funds. Before H.I.G., he worked at General Electric Company and GE Capital, including on the GE Corporate Finance Staff, and holds a B.S. in Economics from Stanford University and an M.B.A. from Harvard Business School.

Bruce Robertson· Senior Advisor· Miami

Senior Advisor at H.I.G. HealthBridge Partners focused on life sciences investments across biopharmaceuticals, medical devices, and diagnostics, with more than 30 years in the sector. Previously Managing Director at Toucan Capital and General Partner at GIV Venture Partners, with earlier roles at IGEN International and W.R. Grace & Co.; he holds degrees from the University of Pennsylvania, University of Delaware, and Harvard Business School.

b•••@higcapital.comreveal

What they invest in

from 12 of 27 portfolio companies

Healthtech ×8Medical Devices ×6Biotech ×5Digital Health ×2Enterprise Software ×2Hardware ×2

HQs:United States×9

Investments · 27 tracked

founders shown can be your intro path

By year:2020 · 1 2018 · 1 2013 · 13 dated

Exagenexagen.comin 𝕏NASDAQ: XGN

Exagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression.

BiotechDigital HealthHealthtechMedical DevicesVista, US

Thierry Dervieux(Executive Officer)Wendy Swedick(Executive Officer)Arthur Weinstein(Director)James L.L. Tullis(Director)Fortunato R. Rocca(Executive Officer, Director)John M. Radak(Director)

Rxsightrxsight.cominNASDAQ: RXST

Neurana PharmaceuticalsDec 2013SEC filingmedium confidence

BiotechSan Diego, US

Kathleen D. Scott(Chief Financial Officer, Secretary and Treasurer)Judy Caron(Chief Operating Officer)David F. Hale(Chairman of the Board of Directors, Acting President and CEO)Brian Dorsey(Director)Daniel Becker(Director)Joshua Richardson(Director)

Board seatAlex Zisson· per SEC Form D · $3.8M raise · filed May 2018

Alder BiopharmaceuticalsJan 2018

BiotechBothell, US

Randall Schatzman(Executive Officer, Director)James Bucher(Executive Officer)Clay Siegall(Director)Jeffrey Smith(Executive Officer)Paul Carter(Director)Randal Hassler(Executive Officer)

Arvelle Therapeuticsangelinipharma.chin

Augmedicsaugmedics.comin 𝕏Jun 2020

Augmedics develops xvision (X2), an augmented reality surgical navigation system that overlays 3D anatomy in the surgeon's field of view for spine procedures.

HardwareHealthtechMedical DevicesArlington Heights, US

Nissan Elimelech(Chief Executive Officer)

BIOVECTRA

Contract development and manufacturing organization (CDMO) providing full-service cGMP outsourcing for intermediates and APIs.

Celerion

Global clinical research organization providing early-stage clinical trial and bioanalytical services, headquartered in Lincoln, NE.

Click Therapeuticsclicktherapeutics.comin 𝕏

Click Therapeutics develops software-based prescription medical treatments for patients with unmet medical needs, combining neuroscience with digital technology to create a new treatment modality.

Digital HealthHealthtechMedical DevicesNew York, US

David B. Klein(Founder and CEO)Randall Stanicky(Executive Officer)Nicholas Schork(Director)Victor Gao(Director)Emile Westergaard(Director)

BoardAlex Zisson(Director)

Cookie Policyhig.comin 𝕏

H.I.G.

Enterprise Software

ForSight VISION5

HealthtechMenlo Park, US

Robert C. Bellas, Jr.(Director)K. Angela Macfarlane(Executive Officer, Director)Jim Glasheen(Director)Andy Corley(Director)Aaron Davidson(Director)William J. Link, Ph.D.(Director)

Highridgehighridgemedical.comin

Highridge Medical is a spine-focused medical device company whose products include the Mobi-C cervical disc for cervical surgery, and it provides medical education for spine surgeons.

HardwareHealthtechMedical Devices

HyperBranch

Develops innovative medical devices for ophthalmology, general, and specialty surgery markets.

Intact Vascularintactvascular.com

Leitersleiters.comin

Leiters Health is an FDA-registered outsourcing provider that compounds high-quality sterile pharmaceutical preparations for hospitals, ophthalmology practices, and surgery centers.

Enterprise SoftwareHealthtechMedical Devices

Navitas Life Sciences

NeuWave

Develops and commercializes energy-based soft tissue ablation devices for various clinical markets.

Nevakar

BiotechBridgewater, US

Navneet Puri(Executive Officer)

Novadaq

Develops and commercializes medical devices based on a proprietary imaging platform for diagnosis and treatment of diseases.

On Target Laboratoriesontargetlabs.comin 𝕏

On Target Labs develops intraoperative molecular imaging agents that enable surgeons to visualize and detect cancerous tissue during procedures.

BiotechHealthtechMedical Devices

Orbus Therapeutics

Brings innovative products to underserved patients affected by rare diseases.

Quinnova Pharmaceuticals

Specialty pharmaceutical company built on patent-protected dermal delivery technologies.

Rising Pharmaceuticals

Develops and markets generic and specialty branded pharmaceutical products, based in New Brunswick, NJ.

Salmedixacquired by Cephalon Inc

Develops oncology drugs for hematologic cancers; acquired by Cephalon Inc. in 2005.

Taconic Biosciences

Leading supplier of murine research models for pharmaceutical, biotechnology, CRO, and academic research clients.

VertiFlex

HealthtechSan Clemente, US

Kathy Tune(Director)Peter Justin Klein(Director)Sigrid Van Bladel(Director)Jeff Swiecki(Executive Officer)Earl R. Fender(Executive Officer, Director)Guy P. Nohra(Director)

Zerigo Health

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 3

IPOs and acquisitions across the tracked portfolio

ExagenNASDAQ: XGNRxsightNASDAQ: RXSTSalmedixacq. by Cephalon Inc

Portfolio news

latest coverage across their companies

XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rating

Exagen · gurufocus.com · Jun 25, 2026

Who is Michael Leiters, potential new CEO of Porsche? | Reuters

Leiters · reuters.com · Oct 17, 2025

Frequently asked questions

What stage does H.I.G. HealthBridge Partners invest at?: H.I.G. HealthBridge Partners invests at the Growth stage.
What is H.I.G. HealthBridge Partners's typical check size?: H.I.G. HealthBridge Partners typically writes checks of $5M – $40M.
What sectors does H.I.G. HealthBridge Partners focus on?: H.I.G. HealthBridge Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is H.I.G. HealthBridge Partners located?: H.I.G. HealthBridge Partners is headquartered in Miami, US.

Images

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.

$50K – $12.7M

B Capital Group

B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

Capricorn Venture Partners

Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.

$5M – $25M

Featured in lists

Investors & VC Firms in United States Growth Investors & VC Firms Investors & VC Firms in Global Healthtech Investors & VC Firms Investors & VC Firms in Europe Biotech Investors & VC Firms Investors & VC Firms in Asia-Pacific Investors & VC Firms in North America Healthtech Investors & VC Firms in United States Growth Investors & VC Firms in United States Growth Investors & VC Firms in Global Medical Devices Investors & VC Firms